Conflict of interest statement: Conflict of interest statement Dr Jones reported 
receiving grants from MSD; and personal fees from Adaptimmune, Athenex, 
Blueprint Medicines Corporation, Clinigen, Eisai, Eli Lilly, Epizyme, Daichii 
Sankyo, Deciphera Pharmaceuticals, Helsinn, Immunedesign, Merck, PharmaMar, 
Tracon and UptoDate outside the submitted work. Dr Serrano reported receiving 
other support from Bayer, Blueprint Medicines Corporation, Deciphera 
Pharmaceuticals, Eli Lilly, Novartis, Pfizer and PharmaMar; and grants from 
Bayer, Deciphera Pharmaceuticals and Pfizer outside the submitted work. Dr von 
Mehren reported receiving other support from Blueprint Medicines Corporation 
during the conduct of the study; and other support from Arog Pharmaceuticals, 
Deciphera Pharmaceuticals, Exelixis and Novartis outside the submitted work. Dr 
George reported receiving research support to her institution from Ariad, Bayer, 
Blueprint Medicines Corporation, Daiichi Sankyo, Deciphera Pharmaceuticals, 
Novartis and Pfizer; and advisory board/consulting fees from AstraZeneca, 
Blueprint Medicines Corporation, Daiichi Sankyo, Deciphera Pharmaceuticals and 
Eli Lilly. Dr Heinrich reported receiving grants and personal fees from 
Blueprint Medicines Corporation; and personal fees and other support from 
Molecular MD during the conduct of the study; personal fees and other from 
Novartis; and grants and personal fees from Deciphera Pharmaceuticals outside 
the submitted work. Dr Heinrich also has a patent “Treatment of Gastrointestinal 
Stromal Tumors” licenced to Novartis, and a patent “Activating Mutations of 
PDGFRA” issued. Dr Kang reported receiving personal fees from ALX Oncology, 
Amgen, Bristol Myers Squibb, Daehwa Pharmaceutical, MacroGenics, Novartis, 
Surface Oncology and Zymeworks outside the submitted work. Dr Schöffski reported 
receiving personal fees from Deciphera Pharmaceuticals; other support from 
Adaptimmune, Blueprint Medicines Corporation, Deciphera Pharmaceuticals, 
Exelixis, Eisai, Eli Lilly, Ellipses Pharma, Genmab, Intellisphere, Loxo 
Oncology, Merck, Plexxikon, Servier and Transgene; and grants from Ipsen and MSD 
outside the submitted work. Dr Cassier reported receiving personal fees from 
Blueprint Medicines Corporation during the conduct of the study; other support 
from AbbVie, Bayer, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, 
Merck Serono, MSD, Novartis and Roche/Genentech; personal fees from Amgen, 
Bristol Myers Squibb, MSD, Novartis and Roche/Genentech; non-financial support 
from MSD and Novartis; and grants from Novartis outside the submitted work. Dr 
Mir reported receiving consulting fees from Eli Lilly, Janssen, Lundbeck, 
Pfizer, Roche, Servier and Vifor Pharma; and owns stock options from Amplitude 
Surgical, Transgene and Ipsen. Dr Chawla reported receiving funding from ADI, 
Amgen, GlaxoSmithKline, Ignyta, Immix Bopharma, Inhibrx, Janssen, Karyopharm 
Therapeutics, Roche, SARC and Tracon outside the submitted work. Dr Eskens has 
nothing to disclose. Dr Rutkowski reported receiving personal fees from 
Blueprint Medicines Corporation, Bristol Myers Squibb, Merck, MSD, Novartis, 
Pierre Fabre, Pfizer, Roche and Sanofi outside the submitted work. Dr Tap 
reported receiving other support from Blueprint Medicines Corporation during the 
conduct of the study; receiving personal fees from Agios Pharmaceuticals, 
Blueprint Medicines Corporation, Daiichi Sankyo, Deciphera Pharmaceuticals, Eli 
Lilly, EMD Serono, Eisai, GlaxoSmithKline, Janssen, Immune Design, Loxo Oncology 
and NanoCarrier outside the submitted work; having a patent Companion Diagnostic 
for CDK4 inhibitors – 14/854,329 pending to MSKCC/SKI; attending scientific 
advisory boards for Atropos Therapeutics and Certis Oncology Solutions; being a 
consultant for Daiichi Sankyo; having stock ownership in Atropos Therapeutics 
and Daiichi Sankyo; and having involvement in an FDA ODAC meeting for 
pexidartinib. Dr Zhou is a former employee of Blueprint Medicines Corporation. 
Dr Roche reported receiving other support from Epizyme outside the submitted 
work; and being a current employee and shareholder of Blueprint Medicines 
Corporation. Dr Bauer reported receiving grants from Blueprint Medicines 
Corporation, Incyte and Novartis; personal fees from Bayer, Blueprint Medicines 
Corporation, Deciphera Pharmaceuticals, Exelixis and Novartis during the conduct 
of the study; and personal fees from ADC Therapeutics, Daiichi Sankyo, Eli 
Lilly, Exelixis, Janssen-Cilag, Nanobiotix, PharmaMar and Plexxikon outside the 
submitted work.